Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine‐induced cognitive deficits in mice

This study was undertaken to examine the effects of CDPPB (3‐cyano‐ N ‐(1,3‐diphenyl‐1 H ‐pyrazol‐5‐yl)benzamide), a positive allosteric modulator ( PAM ) of metabotropic glutamate receptor 5 (m G lu 5 ), on cognitive deficits in mice after repeated administration of the N ‐methyl‐ D ‐aspartate ( NMDA ) receptor antagonist phencyclidine ( PCP ). In the novel object recognition test, PCP (10 mg/kg/day for 10 days)‐induced cognitive deficits in mice were not improved by a single administration of CDPPB (10 mg/kg/day). However, PCP (10 mg/kg/day for 10 days)‐induced cognitive deficits in mice were significantly improved by subsequent subchronic (14 days) administration of CDPPB (10 mg/kg/day), but not of CDPPB (1.0 mg/kg/day). This study suggests that PCP ‐induced cognitive deficits in mice are improved by subsequent subchronic administration of CDPPB . Therefore, m G lu 5 PAM s would be potential therapeutic drugs for cognitive deficits in schizophrenia.